David Swinney,
Chief Executive Officer
Dr. Swinney is co-founder of iRND3 and has over 20 years broad experience with Syntex and Roche as a leader in pre-clinical drug discovery, primarily in the inflammation and virology disease areas. His previous position was Director of Virology Biochemical Pharmacology at Roche Palo Alto. Dr. Swinney has devoted the majority of his career to the identification of tractable drug targets, effective mechanisms of drug action, and promising leads and clinical candidates to address unmet medical needs. He has also developed an expertise in the understanding and application of binding kinetics of drug discovery. Dr. Swinney has a PhD in medicinal chemistry from the University of Washington and is author of over 100 publications in the fields of biochemistry and pharmacology.
|
|
|
